Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite
12:10pm, Thursday, 04'th Jun 2026
This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.
Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the peace n
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts,
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstrac
Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged
09:11am, Wednesday, 27'th May 2026
Guardant Health stock spiked Wednesday after the American Cancer Society recommended its blood test as a screening tool for colon cancer.
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
08:00am, Wednesday, 27'th May 2026
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield⢠blood test is now included in updated Ameri
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
07:47am, Wednesday, 27'th May 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American C
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
12:07pm, Wednesday, 20'th May 2026
The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.'s (NASDAQ:GH) Guardant360 Liquid CDx test, expanding the company's blood-based comprehensive genomic profiling ca
Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?
10:57am, Wednesday, 20'th May 2026
The Food and Drug Administration approved Guardant Health's newest blood cancer test Wednesday, and the stock leaped to a three-month high.
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
09:00am, Wednesday, 20'th May 2026
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
08:05am, Wednesday, 20'th May 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360�
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:51pm, Monday, 18'th May 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of
Guardant Health: Reveal And Shield Driving The Next Growth Phase
02:36pm, Friday, 15'th May 2026
Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrade
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:00pm, Tuesday, 12'th May 2026
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
05:21am, Friday, 08'th May 2026
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
